Mechanism Summary

Thymosin alpha-1 (thymalfasin) is a synthetically manufactured 28-amino-acid acetylated polypeptide identical to a naturally occurring human thymic peptide; it is described as activating toll-like receptor 9 (TLR9) signaling on dendritic cells, driving Th1 polarization and T-cell maturation as part of coordinated adaptive immune responses.

Pathways

References

• https://www.fda.gov/media/183892/download
• https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=thymalfasin
• https://pubmed.ncbi.nlm.nih.gov/39814420/
• +7 more

Notes

Expansion-batch evidence packet requires human review before publication. | Sepsis efficacy evidence is discordant between the early ETASS trial and the later, larger TESTS trial; resolve via an independent systematic review/meta-analysis source not yet fetched. | A conflicting FDA-approval claim from a public-docket presentation was identified but not independently reconciled against a primary orphan-drug-designation or NDA history record. | UNII and ChEMBL identifiers not yet resolved from structured databases; two candidate CAS numbers (62304-98-7 and 69521-94-4) were found and only one was selected without independent confirmation of which corresponds to free base vs. acetate salt. | Ex-U.S. approval-country claims rest on a secondary informational source, not a primary foreign regulator page or label registry. | Compiled draft requires human review before publication.